SAR Sareum Holdings plc

LSE · GB · Healthcare · Biotechnology · sareum.com

29.50GBp-1.67%Mkt Cap: 44.80M $P/E: —Today

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a T…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap44.80M USD

Enterprise Value42.20M USD

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-4.82M USD

Revenue/Share—

Last Price29.50 GBp

Fiscal Year EndJun 2025

MR QuarterDec 2025

Employees5

CountryGB

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-0.08

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B33.33

EPS (TTM)-0.04

EPS (Forward)-3.60

52W Range

9.50066% of range40.00

52W High40.00 GBp

52W Low9.500 GBp

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-194.91%

ROA-104.92%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-2.77M USD

CapEx (TTM)—

FCF Margin—

FCF Yield-2.28%

Net Debt-2.70M USD

Net Debt/EBITDA—

Balance Sheet

Debt/Equity—

Current Ratio1.58

Quick Ratio1.58

Book Value/Sh0.0090 GBp

Cash/Share0.02 GBp

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 GBp

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split1:50

Split DateMar 1, 2022

Analyst Consensus

Rating—

Target (Mean)41.60 GBp

Upside (mean)+41.0%

Target Range41.60 GBp – 41.60 GBp

# Analysts1

Ownership

Shares Out.139.73M

Float132.72M

Insiders3.72%

Institutions0.00%

Technical

SMA 5029.06 (+1.5%)

SMA 20021.75 (+35.6%)

Beta-0.55

S&P 52W Chg14.58%

Avg Vol (30d)315.33K

Avg Vol (10d)257.58K

Technical Indicators

RSI (14)47.9

MACD0.3833

MACD Signal0.7174

MACD Hist.-0.3340

BB Upper33.06 GBp

BB Middle31.10 GBp

BB Lower29.14 GBp

BB Width12.62%

ATR (14)2.055 GBp

Vol Ratio (20d)3.54x